| Product/ Candidate |
Therapeutic Area |
Discovery and Translation |
POC | Pivotal | Commercial | Content Partner |
|---|---|---|---|---|---|---|
 ** |
Substance Use Disorder |  |
||||
 ** |
Opioid Use Disorder | |
||||
 |
Chronic Insomnia |  |
||||
| PEAR-004* | Schizophrenia | |||||
| DISCOVERY* | IBS |  *** |
||||
| DISCOVERY* | Pain |  |
||||
| DISCOVERY* | PTSD |  |
||||
| DISCOVERY* | Migraine |  |
||||
| DISCOVERY* | Bipolar Disorder | |||||
| PEAR-006* | Multiple Sclerosis | |||||
| DISCOVERY* | Epilepsy | |||||
| DISCOVERY* | Specialty GI |  **** |
||||
| DISCOVERY* | Oncology |  |
||||
| PLATFORM | Voice Analytics |   |
||||
* FDA has not determined the safety or effectiveness of this product candidate.
** Licensed content from an individual researcher employed by Dartmouth.
*** Licensed content from individual researchers employed by the Karolinska Institute.
**** Pear entered into a services agreement with Ironwood to evaluate the development of a PDT in GI diseases.